Key result
Vascular surgery requires holding oral factor Xa inhibitors for 72 hours and dabigatran for 96 hours.
Why the study?
Many patients receiving DOACs routinely are scheduled for invasive surgical procedures and need specific perioperative management, particularly given expanding indications in vascular surgery.
This review discusses the perioperative management and reversal of direct oral anticoagulants in patients undergoing vascular surgery.
Answers are grounded in this paper and cite their sources.
May inform perioperative DOAC timing before elective vascular surgery; leaves open prospective outcome trials.
Since their first approval in 2010, direct oral anticoagulants (DOACs) have become attractive for anticoagulant treatment. DOACs are indicated for the prevention and treatment of several cardiovascular conditions and have now emerged as leading therapeutic options. Every year, large number of patients receiving DOACs routinely are scheduled for invasive surgical procedures and need specific perioperative management. Moreover, recently published trials have provided arguments for a larger future use of DOACs, including during the postoperative period after vascular surgery and for high-risk cardiovascular patients. In this communication, we discuss the perioperative management of DOACs for patients undergoing vascular surgery.
No takes yet. Share an insight, caveat, or question.
Houben et al. (2023) conducted a review in Patients receiving DOACs scheduled for vascular surgery. Direct oral anticoagulants (DOACs) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: